The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: Outcome study in clinical practice

G. Lelli, S. Cataldo, I. Carandina, B. Urbini, F. Bonetti, M. Marzola, G. Biasco, M. A. Pantaleo, A. Brandes, C. Calandri, E. Ravaioli, O. Nanni, C. Boni, C. Banzi, F. Negri, A. Panetta, F. Di Fabio, D. Turci

Research output: Contribution to journalArticlepeer-review

Abstract

We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with irinotecan (93.8%). A 45% disease control rate (complete plus partial responses plus stable disease) was obtained in 55 patients and was related to absence of weight loss (p<0.0001) and high grade (≥2) skin toxicity (p<0.0001). Median time to progression (TTP) was 4 months (95%CI 2.7-5.3) and median overall survival (OS) was 11.8 months (95%CI 8.5-15.1). Performance status ≤1, no weight loss and high grade (≥2) skin toxicity were related both to a longer TTP (p=0.035, p=0.035, p=0.0017) and OS (p<0.0001, p<0.0001, p=0.006). According to multivariate analysis, the absence of weight loss was related to longer TTP (HR 0.331, p=0.004) and OS (HR 0.176, p<0.0001), and EGFR over-expression (3+) to longer TTP (HR 0.402, p=0.020).

Original languageEnglish
Pages (from-to)374-379
Number of pages6
JournalJournal of Chemotherapy
Volume20
Issue number3
Publication statusPublished - Jun 2008

Keywords

  • Appropriate prescriptions
  • Clinical outcome
  • Multicenter study
  • Palliative treatment
  • Retrospective study
  • Targeted therapies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: Outcome study in clinical practice'. Together they form a unique fingerprint.

Cite this